A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Study Purpose

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements. 4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 5. Subjects must have a documented diagnosis of MM and measurable disease at enrollment. Measurable disease is defined as:
  • - M-protein quantities ≥ 0.5 g/dL by sPEP or.
  • - ≥ 200 mg/24 hour urine collection by uPEP or.
  • - Serum FLC levels > 100 mg/L (milligrams/liter) involved light chain and an abnormal kappa/lambda (κ/λ) ratio in subjects without measurable serum or urine M-protein or.
  • - For subjects with immunoglobulin class A (IgA), myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level ≥ 0.50 g/dL.
6. All subjects must have:
  • - Received at least 3 prior anti-myeloma regimens including at least 2 consecutive cycles of lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid and a CD38 antibody (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one regimen).
  • - Documented disease progression on or within 60 days from the last dose of their last myeloma therapy.
  • - Subjects who had CAR-T therapy as their last myeloma therapy are eligible as long as they have documented disease progression following CAR-T therapy.
  • - In addition to criteria above (a and b), subjects enrolled in Part 2 must have disease refractory to an immunomodulatory agent (lenalidomide and/or pomalidomide), a glucocorticoid, a proteasome inhibitor, and a CD38 antibody.
Refractory is defined as disease that is nonresponsive on therapy (failure to achieve minimal response or development of progressive disease), or progresses within 60 days of last dose. 7. Subjects must have the following laboratory values:
  • - Absolute neutrophil count (ANC) ≥ 1.25 x 109/L without growth factor support for ≥ 7 days (≥ 14 days for pegfilgrastim).
ANC of ≥ 1.00 x 109/L is permitted for the dose expansion cohorts (Part 2).
  • - Hemoglobin (Hgb) ≥ 8 g/dL.
  • - Platelets (plt) ≥ 75 x 109/L without transfusion for ≥ 7 days.
  • - Corrected serum calcium ≤ 13.5 mg/dL (≤ 3.4 mmol/L).
  • - Creatinine clearance (CrCl) based on Cockcroft-Gault formula ≥ 45 mL/min.
  • - AST/SGOT and ALT/SGPT ≤ 3.0 x upper limit of normal (ULN).
  • - Serum bilirubin ≤ 1.5 x ULN or < 3.0 mg/dL for subjects with documented Gilbert's syndrome.
  • - Uric acid ≤ 7.5 mg/dL (446 µmol/L).
  • - PT/INR < 1.5 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN, (for subjects not receiving therapeutic anticoagulation).
8. Females of childbearing potential (FCBP) must:
  • - Have two negative pregnancy tests as verified by the Investigator prior to starting study therapy.
She must agree to ongoing pregnancy testing during the course of the study, and after discontinuation of CC-92480. This applies even if the subject practices true abstinence* from heterosexual contact.
  • - Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, two reliable forms of contraception as defined in the PPP and provided to the subject at the time of informed consent, without interruption, 28 days prior to starting CC-92480, during the study therapy (including during dose interruptions), and for 28 days after discontinuation of study therapy.
Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point and, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). 1. Male subjects must: Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use of a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study (even during dose interruptions) and for at least 3 months following CC-92480 discontinuation in accordance with the PPP provided to the subject at the time of informed consent, even if he has undergone a successful vasectomy. * True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and coitus interruptus (withdrawal) are not acceptable methods of contraception. 2. Males must agree to refrain from donating sperm while on CC-92480 for 90 days after its discontinuation. Females must agree to refrain from donating ova while on CC-92480 for 28 days after its discontinuation. 3. All subjects must agree to refrain from donating blood while on CC-92480 and for 28 days after its discontinuation.

Exclusion Criteria:

1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. 3. Subject has any condition that confounds the ability to interpret data from the study. 4. Subject has non-secretory multiple myeloma. 5. Subject has refractory primary multiple myeloma (ie, no history of at least a minor response to a prior treatment regimen). 6. Subject has plasma cell leukemia or active leptomeningeal myelomatosis. 7. Subject has documented, systemic light chain amyloidosis or Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome. 8. Subject has immunoglobulin class M (IgM) myeloma. 9. Part 1: Subject has a history of allogeneic bone marrow transplantation. Part 2: Subject has a history of allogeneic bone marrow transplantation within 6 months prior to first dose. Subject should not have ongoing graft-versus-host disease (GVHD) requiring systemic immunosuppression. 10. Subject is undergoing dialysis. 11. Subjects with peripheral neuropathy ≥ Grade 2. 12. Subjects with gastrointestinal disease that may significantly alter the absorption of CC-92480. 13. Subject has impaired cardiac function or clinically significant cardiac disease, including any of the following:
  • - LVEF < 45% as determined by ECHO or MUGA scan at Screening.
  • - Complete left bundle branch, bifascicular block or other clinically significant abnormal electrocardiographic (ECG) finding at Screening.
  • - A prolongation of QT interval on Screening ECG as defined by repeated demonstration of a QTc interval >480 milliseconds (ms) using Fridericia's QT correction formula; a history of or current risk factors for Torsades de Pointe (eg, heart failure, hypokalemia, or a family history of Long QT Syndrome); and concurrent administration of medications that prolong the QT/QTc interval.
  • - Congestive heart failure (New York Heart Association Class III or IV).
  • - Myocardial infarction ≤6 months prior to starting CC-92480.
  • - Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris.
14. Concurrent administration of strong CYP3A modulators; concurrent administration of proton-pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, pantoprazole) ≤ 2 weeks prior to starting CC-92480. 15. Subject had prior systemic myeloma treatment with an investigational anti-myeloma agent (eg, anti-PD-1, anti-PD-L1) ≤ 5 half-lives prior to starting CC-92480 (not applicable for subjects who had CAR-T as last prior regimen); subject had prior exposure to approved myeloma therapies (including therapeutic monoclonal antibodies such as anti-CD38 or anti-SLAM-7) ≤ 5 half-lives or within 4 weeks prior to starting CC-92480 whichever is shorter. 16. Subject had major surgery ≤ 2 weeks prior to starting CC-92480. Note: Subjects must have recovered from any clinically significant effects of recent surgery. 17. Subject is a pregnant or nursing female, or intends to become pregnant or donate ova during participation in the study. 18. Subject has known human immunodeficiency virus (HIV) infection. 19. Subject has known active chronic hepatitis B or C virus (HBV/HCV) infection. 20. Subject has a history of concurrent second cancer requiring ongoing systemic treatment. 21. Subjects has a history of prior malignancy other than MM, except if the subject has been free of disease for ≥3 years OR the subject had one of the following noninvasive malignancies treated with curative intent without known recurrence:
  • - Basal or squamous cell carcinoma of the skin.
  • - Carcinoma in situ of the cervix or breast.
  • - Stage 1 bladder cancer.
  • - Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the Tumor/Node/Metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent.
22. Subject has a history of anaphylaxis to thalidomide, lenalidomide, pomalidomide or dexamethasone. 23. Subject has known or suspected hypersensitivity to the excipients (excipients include silica dimethyl silylate, anhydrous colloidal silicon dioxide, mannitol, fumaric acid and stearic acid) contained in the formulation of CC-92480 or dexamethasone. 24. Subject has undergone either of the following within 14 days of initiating CC-92480:
  • - Plasmapheresis.
  • - Radiation therapy other than local therapy for symptomatic relief of MM associated bone lesions.
25. Subject has received immunosuppressive medication within 14 days prior to the first dose of CC-92480. The following are exceptions to this criterion:
  • - Intranasal, inhaled, topical or local corticosteroid injections (eg, intra-articular injection).
  • - Systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone or the equivalent.
  • - Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication).
26. Subject is unable or unwilling to undergo protocol required venous thromboembolism (VTE) prophylaxis.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03374085
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Celgene
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Australia, Belgium, Canada, Denmark, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions

Arms

Experimental: Administration of CC-92480 in combination with dexamethasone

Escalating doses of CC-92480 and in combination with a fixed dose of dexamethasone administered according to different dosing schedules

Experimental: Administration of CC-92480 monotherapy

Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules

Interventions

Drug: - CC-92480

CC-92480

Drug: - Dexamethasone

Dexamethasone

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

City of Hope Cancer Center, Duarte, California

Status

Recruiting

Address

City of Hope Cancer Center

Duarte, California, 91010-300

City of Hope Cancer Center, Duarte, California

Status

Recruiting

Address

City of Hope Cancer Center

Duarte, California, 91010-300

Site Contact

Scott Goldsmith, Site 103

Clinical.Trials@bms.com

855-907-3286

Colorado Blood Cancer Institute, Denver, Colorado

Status

Not yet recruiting

Address

Colorado Blood Cancer Institute

Denver, Colorado, 80218

Emory Clinic, Atlanta, Georgia

Status

Recruiting

Address

Emory Clinic

Atlanta, Georgia, 30322

Emory Clinic, Atlanta, Georgia

Status

Recruiting

Address

Emory Clinic

Atlanta, Georgia, 30322

Site Contact

Sagar Lonial, Site 102

Clinical.Trials@bms.com

404-778-1900

Dana Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana Farber Cancer Institute

Boston, Massachusetts, 02115

Dana Farber Cancer Institute, Boston, Massachusetts

Status

Recruiting

Address

Dana Farber Cancer Institute

Boston, Massachusetts, 02115

Site Contact

Paul Richardson, Site 105

Clinical.Trials@bms.com

617-632-6624

Roswell Park Cancer Center, Buffalo, New York

Status

Not yet recruiting

Address

Roswell Park Cancer Center

Buffalo, New York, 14263

Roswell Park, Buffalo, New York

Status

Recruiting

Address

Roswell Park

Buffalo, New York, 14263

Site Contact

Jens Hillengass, Site 111

Clinical.Trials@bms.com

716-845-3221

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Memorial Sloan Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Site Contact

Malin Hultcrantz, Site 104

Clinical.Trials@bms.com

646-608-3714

Gibbs Cancer Center & Research, Spartanburg, South Carolina

Status

Not yet recruiting

Address

Gibbs Cancer Center & Research

Spartanburg, South Carolina, 29303

Sarah Cannon Cancer Center, Nashville, Tennessee

Status

Recruiting

Address

Sarah Cannon Cancer Center

Nashville, Tennessee, 37203

Sarah Cannon Cancer Center, Nashville, Tennessee

Status

Recruiting

Address

Sarah Cannon Cancer Center

Nashville, Tennessee, 37203

Site Contact

Jesus Berdeja, Site 101

Clinical.Trials@bms.com

615-329-0570

Houston, Texas

Status

Recruiting

Address

MD Anderson Cancer Center The University of Texas

Houston, Texas, 77030

Houston, Texas

Status

Recruiting

Address

MD Anderson Cancer Center The University of Texas

Houston, Texas, 77030

Site Contact

Robert Orlowski, Site 106

Clinical.Trials@bms.com

713-792-2860

University of Virginia Cancer, Charlottesville, Virginia

Status

Active, not recruiting

Address

University of Virginia Cancer

Charlottesville, Virginia, 22903

University Of Virginia, Charlottesville, Virginia

Status

Recruiting

Address

University Of Virginia

Charlottesville, Virginia, 22908

Site Contact

Laahn Foster, Site 112

Clinical.Trials@bms.com

434-982-6517

University of WA School of Medicine, Seattle, Washington

Status

Active, not recruiting

Address

University of WA School of Medicine

Seattle, Washington, 98104

Seattle, Washington

Status

Recruiting

Address

University Of Washington School Of Medicine

Seattle, Washington, 98104

Site Contact

Andrew Cowan, Site 109

Clinical.Trials@bms.com

855-907-3286

International Sites

Local Institution - 804, Camperdown, New South Wales, Australia

Status

Recruiting

Address

Local Institution - 804

Camperdown, New South Wales, 2050

Site Contact

Site 804

Clinical.Trials@bms.com

855-907-3286

Royal Prince Albert Hospital, Camperdown, New South Wales, Australia

Status

Recruiting

Address

Royal Prince Albert Hospital

Camperdown, New South Wales, 2050

Local Institution - 802, Adelaide, South Australia, Australia

Status

Recruiting

Address

Local Institution - 802

Adelaide, South Australia, 5000

Site Contact

Site 802

Clinical.Trials@bms.com

855-907-3286

Royal Adelaide Hospital, Adelaide, South Australia, Australia

Status

Recruiting

Address

Royal Adelaide Hospital

Adelaide, South Australia, 5000

Local Institution - 805, Clayton, Victoria, Australia

Status

Recruiting

Address

Local Institution - 805

Clayton, Victoria, 3168

Site Contact

Site 805

Clinical.Trials@bms.com

855-907-3286

Monash Medical Centre, Clayton, Victoria, Australia

Status

Recruiting

Address

Monash Medical Centre

Clayton, Victoria, 3168

St.Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

Status

Recruiting

Address

St.Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065

Local Institution - 803, Melbourne, Victoria, Australia

Status

Recruiting

Address

Local Institution - 803

Melbourne, Victoria, 3004

Site Contact

Site 803

Clinical.Trials@bms.com

855-907-3286

The Alfred Hospital, Melbourne, Victoria, Australia

Status

Recruiting

Address

The Alfred Hospital

Melbourne, Victoria, 3065

Local Institution - 806, Fitzroy, Australia

Status

Recruiting

Address

Local Institution - 806

Fitzroy, , 3065

Site Contact

Site 806

Clinical.Trials@bms.com

855-907-3286

CHU Mont-Godinne, Yvoir, Namur, Belgium

Status

Not yet recruiting

Address

CHU Mont-Godinne

Yvoir, Namur, 5530

UZ Gent, Gent, Oost-Vlaanderen, Belgium

Status

Not yet recruiting

Address

UZ Gent

Gent, Oost-Vlaanderen, 9000

UZ Leuven, Leuven, Wallon, Belgium

Status

Not yet recruiting

Address

UZ Leuven

Leuven, Wallon, 3000

Local Institution - 904, Antwerpen, Belgium

Status

Recruiting

Address

Local Institution - 904

Antwerpen, , 2060

Site Contact

Site 904

Clinical.Trials@bms.com

855-907-3286

UZ Leuven, Antwerpen, Belgium

Status

Not yet recruiting

Address

UZ Leuven

Antwerpen, , 2060

Local Institution - 905, Gent, Belgium

Status

Recruiting

Address

Local Institution - 905

Gent, , 9000

Site Contact

Site 905

Clinical.Trials@bms.com

855-907-3286

Local Institution - 901, Leuven, Belgium

Status

Recruiting

Address

Local Institution - 901

Leuven, , 3000

Site Contact

Site 901

Clinical.Trials@bms.com

855-907-3286

Local Institution - 902, Yvoir, Belgium

Status

Recruiting

Address

Local Institution - 902

Yvoir, , 5530

Site Contact

Site 902

Clinical.Trials@bms.com

855-907-3286

Local Institution - 201, Calgary, Alberta, Canada

Status

Recruiting

Address

Local Institution - 201

Calgary, Alberta, T2N 4N2

Site Contact

Site 201

Clinical.Trials@bms.com

855-907-3286

Tom Baker Cancer Center, Calgary, Alberta, Canada

Status

Recruiting

Address

Tom Baker Cancer Center

Calgary, Alberta, T2N 4N2

Local Institution - 204, London, Ontario, Canada

Status

Recruiting

Address

Local Institution - 204

London, Ontario, N6C 6B5

Site Contact

Site 204

Clinical.Trials@bms.com

855-907-3286

London Health Sciences Centre, London, Ontario, Canada

Status

Recruiting

Address

London Health Sciences Centre

London, Ontario, N6C 6B5

Local Institution - 205, Ottawa, Ontario, Canada

Status

Recruiting

Address

Local Institution - 205

Ottawa, Ontario, K1H 8L6

Site Contact

Site 205

Clinical.Trials@bms.com

855-907-3286

Ottawa General Hospital, Ottawa, Ontario, Canada

Status

Recruiting

Address

Ottawa General Hospital

Ottawa, Ontario, K1H 8L6

Local Institution - 202, Toronto, Ontario, Canada

Status

Recruiting

Address

Local Institution - 202

Toronto, Ontario, M5G 2M9

Site Contact

Site 202

Clinical.Trials@bms.com

855-907-3286

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Status

Recruiting

Address

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9

Local Institution - 206, Montreal, Quebec, Canada

Status

Recruiting

Address

Local Institution - 206

Montreal, Quebec, H4A 3J1

Site Contact

Site 206

Clinical.Trials@bms.com

855-907-3286

McGill, Montreal, Quebec, Canada

Status

Recruiting

Address

McGill

Montreal, Quebec, H4A 3J1

CHUQ, Quebec, Canada

Status

Recruiting

Address

CHUQ

Quebec, , G1R 2J6

Local Institution - 203, Quebec, Canada

Status

Recruiting

Address

Local Institution - 203

Quebec, , G1R 2J6

Site Contact

Site 203

Clinical.Trials@bms.com

855-907-3286

Odense University Hospital, Odense, Syddanmark, Denmark

Status

Recruiting

Address

Odense University Hospital

Odense, Syddanmark, 5000

Local Institution - 503, Aarhus N, Denmark

Status

Recruiting

Address

Local Institution - 503

Aarhus N, , DK-8200

Site Contact

Site 503

Clinical.Trials@bms.com

855-907-3286

Local Institution - 501, Copenhagen, Denmark

Status

Recruiting

Address

Local Institution - 501

Copenhagen, , 2100

Site Contact

Site 501

Clinical.Trials@bms.com

855-907-3286

Rigshospitalet University Hospital, Copenhagen, Denmark

Status

Recruiting

Address

Rigshospitalet University Hospital

Copenhagen, , 2100

Local Institution - 502, Odense, Denmark

Status

Recruiting

Address

Local Institution - 502

Odense, , 5000

Site Contact

Site 502

Clinical.Trials@bms.com

855-907-3286

Helsinki University Hospital, Helsinki, Finland

Status

Recruiting

Address

Helsinki University Hospital

Helsinki, , 00029

Local Institution - 601, Helsinki, Finland

Status

Recruiting

Address

Local Institution - 601

Helsinki, , 00029

Site Contact

Site 601

Clinical.Trials@bms.com

855-907-3286

Local Institution - 001, Athens, Greece

Status

Recruiting

Address

Local Institution - 001

Athens, , 11528

Site Contact

Site 001

Clinical.Trials@bms.com

855-907-3286

Kobe City Medical Center, Kobe, Hyogo, Japan

Status

Recruiting

Address

Kobe City Medical Center

Kobe, Hyogo, 650-0047

Local Institution - 705, Chuo-ku,chiba, Japan

Status

Recruiting

Address

Local Institution - 705

Chuo-ku,chiba, , 260-8677

Site Contact

Site 705

Clinical.Trials@bms.com

855-907-3286

Kyushu Medical Center, Fukuoka, Japan

Status

Recruiting

Address

Kyushu Medical Center

Fukuoka, , 810-8563

Local Institution - 704, Kashiwa, Japan

Status

Recruiting

Address

Local Institution - 704

Kashiwa, , 277-8577

Site Contact

Site 704

Clinical.Trials@bms.com

855-907-3286

Local Institution - 701, Okayama, Japan

Status

Recruiting

Address

Local Institution - 701

Okayama, , 701-1192

Site Contact

Site 701

Clinical.Trials@bms.com

855-907-3286

Okayama Medical Center, Okayama, Japan

Status

Recruiting

Address

Okayama Medical Center

Okayama, , 701-1192

Seoul National University Hospital, Seoul, Gyeonggido, Korea, Republic of

Status

Recruiting

Address

Seoul National University Hospital

Seoul, Gyeonggido, 03080

Severance Hospital, Seoul, Gyeonggido, Korea, Republic of

Status

Recruiting

Address

Severance Hospital

Seoul, Gyeonggido, 03722

Local Institution - 150, Seoul, Korea, Republic of

Status

Recruiting

Address

Local Institution - 150

Seoul, , 135-710

Site Contact

Site 150

Clinical.Trials@bms.com

855-907-3286

Local Institution - 151, Seoul, Korea, Republic of

Status

Recruiting

Address

Local Institution - 151

Seoul, , 3080

Site Contact

Site 151

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario Marques, Santander, Cantabria, Spain

Status

Recruiting

Address

Hospital Universitario Marques

Santander, Cantabria, 39008

Hospital Quironsalud Madrid, Madrid, Comunidad De Madrid, Spain

Status

Recruiting

Address

Hospital Quironsalud Madrid

Madrid, Comunidad De Madrid, 28223

Badalona (Barcelona), Spain

Status

Recruiting

Address

Hospital Universitari Germans Trias i Pujol Can Ruti

Badalona (Barcelona), , 08916

Local Institution - 403, Badalona (Barcelona), Spain

Status

Recruiting

Address

Local Institution - 403

Badalona (Barcelona), , 08916

Site Contact

Site 403

Clinical.Trials@bms.com

855-907-3286

Local Institution - 407, Barcelona, Spain

Status

Recruiting

Address

Local Institution - 407

Barcelona, , 08025

Site Contact

Site 407

Clinical.Trials@bms.com

855-907-3286

Hospital San Pau, Barcelona, Spain

Status

Recruiting

Address

Hospital San Pau

Barcelona, , 8025

Hospital San Pedro de Alcantara, Caceres, Spain

Status

Recruiting

Address

Hospital San Pedro de Alcantara

Caceres, , 10003

Local Institution - 406, Caceres, Spain

Status

Recruiting

Address

Local Institution - 406

Caceres, , 10003

Site Contact

Site 406

Clinical.Trials@bms.com

855-907-3286

Hospital 12 de Octobre, Madrid, Spain

Status

Recruiting

Address

Hospital 12 de Octobre

Madrid, , 28041

Local Institution - 404, Madrid, Spain

Status

Recruiting

Address

Local Institution - 404

Madrid, , 28041

Site Contact

Site 404

Clinical.Trials@bms.com

855-907-3286

Clínica Universidad de Navarra, Pamplona, Spain

Status

Recruiting

Address

Clínica Universidad de Navarra

Pamplona, , 31008

Local Institution - 401, Pamplona, Spain

Status

Recruiting

Address

Local Institution - 401

Pamplona, , 31008

Site Contact

Site 401

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario de Salamanca, Salamanca, Spain

Status

Recruiting

Address

Hospital Universitario de Salamanca

Salamanca, , 37007

Local Institution - 402, Salamanca, Spain

Status

Recruiting

Address

Local Institution - 402

Salamanca, , 37007

Site Contact

Site 402

Clinical.Trials@bms.com

855-907-3286

Hospital Universitario La Fe, Valencia, Spain

Status

Recruiting

Address

Hospital Universitario La Fe

Valencia, , 46026

Local Institution - 405, Valencia, Spain

Status

Recruiting

Address

Local Institution - 405

Valencia, , 46026

Site Contact

Site 405

Clinical.Trials@bms.com

855-907-3286

Local Institution - 304, Plymouth, Devon, United Kingdom

Status

Recruiting

Address

Local Institution - 304

Plymouth, Devon, PL6 8DH

Site Contact

Site 304

Clinical.Trials@bms.com

855-907-3286

University Hospital of Wales, Cardiff, Wales, United Kingdom

Status

Recruiting

Address

University Hospital of Wales

Cardiff, Wales, CF14 4XW

Local Institution - 306, Cardiff, United Kingdom

Status

Recruiting

Address

Local Institution - 306

Cardiff, , CF14 4XW

Site Contact

Site 306

Clinical.Trials@bms.com

855-907-3286

Local Institution - 303, London, United Kingdom

Status

Recruiting

Address

Local Institution - 303

London, , NW1 2PG

Site Contact

Site 303

Clinical.Trials@bms.com

855-907-3286

London, United Kingdom

Status

Recruiting

Address

University College London Hospitals Cancer Clinical Trials Unitist FloorCentral wing

London, , NW1 2PG

Local Institution - 305, Newcastle Upon Tyne, United Kingdom

Status

Recruiting

Address

Local Institution - 305

Newcastle Upon Tyne, , NE7 7DN

Site Contact

Site 305

Clinical.Trials@bms.com

855-907-3286

Oxford, United Kingdom

Status

Recruiting

Address

Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine

Oxford, , 0X3 7LE

Local Institution - 302, Oxford, United Kingdom

Status

Recruiting

Address

Local Institution - 302

Oxford, , OX3 7LE

Site Contact

Site 302

Clinical.Trials@bms.com

855-907-3286

Local Institution - 301, Sutton, United Kingdom

Status

Recruiting

Address

Local Institution - 301

Sutton, , SM2 5PT

Site Contact

Site 301

Clinical.Trials@bms.com

855-907-3286

The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Status

Recruiting

Address

The Royal Marsden NHS Foundation Trust

Sutton, , SM2 5PT